Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye.

Objective: Integrating heart failure (HF) guideline recommendations into clinical practice takes time and is often suboptimal in real-life settings. Physician-related factors may be significant barriers to the adoption of these guidelines. This survey aims to assess the current opinions of cardiologists practicing in Türkiye regarding the management of heart failure with reduced ejection fraction (HFrEF).
Methods: The survey comprised 22 questions and was published on the SurveyMonkey platform.
Results: A total of 177 cardiologists (mean age: 39.5 years; 73.3% male) participated in the survey. Of these, 38.7% worked in a training and research hospital, and 10.2% were specialists in HF. The threshold EF value to define HFrEF was ≤ 40% for 80.1% of the cardiologists. While 52.6% of physicians considered angiotensin receptor-neprilysin inhibitor (ARNi) treatment the most effective medication for HF, 62.7% would initiate HF treatment with an angiotensin-converting enzyme inhibitor (ACEi) instead of ARNi due to reimbursement and cost issues. More than half of the cardiologists (52.3%) stated that adding another class of HF medication is more important than up-titrating those already prescribed. Although 69.5% of the study participants indicated prescribing all four classes of HF medications during the initial hospitalization is feasible, most cardiologists preferred a sequential approach starting with ACEi/ARNi, followed by beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Conclusion: This survey highlights significant discrepancies between guideline recommendations and the real-life clinical practice of cardiologists in Türkiye. These results suggest that there is a need for organized action by healthcare providers to improve the implementation of guideline recommendations.